Pfizer Ltd vs Viyash Scientific Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 08, 2026

Key Highlights

The Latest Trading Price of Pfizer Ltd is ₹ 4811 as of 08 May 15:30 . The P/E Ratio of Pfizer Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Viyash Scientific Ltd changed from 62.7 on March 2021 to 150.3 on March 2025 . This represents a CAGR of 19.11% over 5 years The Market Cap of Pfizer Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Viyash Scientific Ltd changed from ₹ 5983 crore on March 2021 to ₹ 3273 crore on March 2025 . This represents a CAGR of -11.36% over 5 years The revenue of Pfizer Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Viyash Scientific Ltd for the Dec '25 is ₹ 872.39 crore as compare to the Sep '25 revenue of ₹ 857.76 crore. This represent the growth of 1.71% The ebitda of Pfizer Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Viyash Scientific Ltd for the Dec '25 is ₹ 148.35 crore as compare to the Sep '25 ebitda of ₹ 178.99 crore. This represent the decline of -17.12% The net profit of Pfizer Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Viyash Scientific Ltd changed from ₹ 9.06 crore to ₹ 48.52 crore over 7 quarters. This represents a CAGR of 160.89% The Dividend Payout of Pfizer Ltd changed from 32.18 % on March 2021 to 98.34 % on March 2025 . This represents a CAGR of 25.03% over 5 yearsThe Dividend Payout of Viyash Scientific Ltd changed from 38.67 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Pfizer Ltd

Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories.
It has its own manufacturing facility at Goa and Thane.
It has the distinction of being the first pharmaceutical company in India to start clinical research.
The Company sells products in nearly 185 countries having 43 manufacturing sites globally.

About Viyash Scientific Ltd

Visistha Traders & Finance Ltd, has amalgamated PI Drugs & Pharmaceuticals Ltd with itself.
The High court has sanctioned the Scheme of Amalgamation and the same was filed with ROC by the company on Nov 12, 2003.

FAQs for the comparison of Pfizer Ltd and Viyash Scientific Ltd

Which company has a larger market capitalization, Pfizer Ltd or Viyash Scientific Ltd?

Market cap of Pfizer Ltd is 22,009 Cr while Market cap of Viyash Scientific Ltd is 9,567 Cr

What are the key factors driving the stock performance of Pfizer Ltd and Viyash Scientific Ltd?

The stock performance of Pfizer Ltd and Viyash Scientific Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Pfizer Ltd and Viyash Scientific Ltd?

As of May 8, 2026, the Pfizer Ltd stock price is INR ₹4811.05. On the other hand, Viyash Scientific Ltd stock price is INR ₹219.0.

How do dividend payouts of Pfizer Ltd and Viyash Scientific Ltd compare?

To compare the dividend payouts of Pfizer Ltd and Viyash Scientific Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.